LTZ Therapeutics

Executive Summary

LTZ Therapeutics is a San Diego-based biotechnology company pioneering novel myeloid cell engager (MCE) immunotherapies for cancer. Founded in 2020, the company employs a reverse translational science approach, leveraging insights from clinical experience and tumor microenvironment biology to design therapeutics that empower myeloid cells. Its platform aims to boost anti-tumor immunity through a three-pronged mechanism: direct myeloid cell engagement, tumor microenvironment reprogramming, and T-cell activation. This differentiated strategy targets the myeloid compartment, which is often overlooked by traditional immunotherapies, and could address resistance mechanisms in solid tumors. The company's focus on myeloid biology represents a promising frontier in immuno-oncology, with potential to complement existing checkpoint inhibitors and CAR-T therapies.

Upcoming Catalysts (preview)

• H2 2026Preclinical data presentation at a major oncology conference (e.g., SITC or AACR)70% success
• 2027IND filing for lead MCE candidate40% success
• 2026Series A financing announcement80% success